PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.23%
EBIT growth above 1.5x AVXL's 13.57%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
45.56%
Operating income growth above 1.5x AVXL's 13.57%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
30.89%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
30.77%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
30.77%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.49%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
98.49%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
94.54%
Positive long-term OCF/share growth while AVXL is negative. John Neff would see a structural advantage in sustained cash generation.
94.54%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
94.54%
Positive 3Y OCF/share CAGR while AVXL is negative. John Neff might see a big short-term edge in operational efficiency.
-8.80%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-8.80%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-8.80%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-273.39%
Negative equity/share CAGR over 10 years while AVXL stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-273.39%
Negative 5Y equity/share growth while AVXL is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-273.39%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.09%
Negative asset growth while AVXL invests at 5629.51%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.63%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
0.22%
Debt shrinking faster vs. AVXL's 19.04%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
-43.90%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.